Jane Street Group LLC bought a new stake in shares of Abrdn Life Sciences Investors (NYSE:HQL) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 22,098 shares of the company’s stock, valued at approximately $290,000. Jane Street Group LLC owned 0.08% of Abrdn Life Sciences Investors as of its most recent filing with the Securities and Exchange Commission.\n\nOther institutional investors have also recently modified their holdings of the company. BankPlus Trust Department bought a new stake in shares of Abrdn Life Sciences Investors during the 4th quarter worth $28,000. Steward Partners Investment Advisory LLC raised its position in Abrdn Life Sciences Investors by 379.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company’s stock valued at $64,000 after purchasing an additional 3,847 shares during the last quarter. Landscape Capital Management L.L.C. bought a new position in Abrdn Life Sciences Investors in the fourth quarter valued at about $154,000. Kapstone Financial Advisors LLC raised its position in Abrdn Life Sciences Investors by 11.0% in the fourth quarter. Kapstone Financial Advisors LLC now owns 13,123 shares of the company’s stock valued at $185,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Guggenheim Capital LLC bought a new position in Abrdn Life Sciences Investors in the fourth quarter valued at about $211,000. 32.21% of the stock is currently owned by institutional investors.\n\nAbrdn Life Sciences Investors Trading Up 1.9%\n\nAbrdn Life Sciences Investors stock opened at $12.55 on Wednesday. Abrdn Life Sciences Investors has a 12 month low of $10.55 and a 12 month high of $15.90. The stock has a 50-day moving average price of $12.14 and a two-hundred day moving average price of $13.14.\n\nAbrdn Life Sciences Investors Announces Dividend\n\nThe company also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Thursday, May 22nd will be given a $0.43 dividend. The ex-dividend date of this dividend is Thursday, May 22nd. This represents a $1.72 annualized dividend and a yield of 13.71%.\n\nInsider Buying and Selling at Abrdn Life Sciences Investors\n\nIn other news, major shareholder Saba Capital Management, L.P. sold 32,922 shares of the stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $13.01, for a total value of $428,315.22. Following the completion of the sale, the insider now owns 3,240,630 shares of the company’s stock, valued at approximately $42,160,596.30. This represents a 1.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders sold 210,080 shares of company stock worth $2,565,065. 10.06% of the stock is currently owned by insiders.\n\nAbrdn Life Sciences Investors Profile\n\nAbrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.

Jane Street Group LLC Takes $290,000 Position in Abrdn Life Sciences Investors (NYSE:HQL)

Jane Street Group LLC and other institutional investors have increased their stakes in Abrdn Life Sciences Investors (NYSE:HQL), with the company announcing a quarterly dividend. The stock's price range and moving averages are also detailed, along with an insider transaction involving Saba Capital Management.